PPP1R14D promotes the proliferation, migration and invasion of lung adenocarcinoma via the PKCα/BRAF/MEK/ERK signaling pathway

Cao,Huijun; Wang,Zhiqiang; Wang,Ying; Ye,Lijuan; Li,Ruilei; Xue,Yuanbo; Li,Ke; Di,Tiannan; Li,Tao; Fan,Zonglin; Liu,Yanyan; Guo,Jiyin; Yao,Hong; Ge,Chunlei

doi:10.3892/ijo.2022.5443

PPP1R14D promotes the proliferation, migration and invasion of lung adenocarcinoma via the PKCα/BRAF/MEK/ERK signaling pathway

Authors:
- Huijun Cao
- Zhiqiang Wang
- Ying Wang
- Lijuan Ye
- Ruilei Li
- Yuanbo Xue
- Ke Li
- Tiannan Di
- Tao Li
- Zonglin Fan
- Yanyan Liu
- Jiyin Guo
- Hong Yao
- Chunlei Ge
View Affiliations

Affiliations: Department of Cancer Biotherapy Center, Yunnan Cancer Hospital, The Third Affiliated Hospital of Kunming Medical University, Kunming, Yunnan 650000, P.R. China, Department of Radiotherapy Oncology, The First Affiliated Hospital of Kunming Medical University, Kunming, Yunnan 650000, P.R. China, Department of Pathology, Yunnan Cancer Hospital, The Third Affiliated Hospital of Kunming Medical University, Kunming, Yunnan 650000, P.R. China, Department of Medical Oncology, Yunnan Cancer Hospital, The Third Affiliated Hospital of Kunming Medical University, Kunming, Yunnan 650000, P.R. China
Published online on: October 19, 2022 https://doi.org/10.3892/ijo.2022.5443
Article Number: 153
Copyright: © Cao et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Protein phosphatase 1 (PP1) inhibitors play a role in tumor progression through different mechanisms. Protein phosphatase 1 regulatory subunit 14D (PPP1R14D) is an inhibitor of PP1. However, the role of PPP1R14D in tumors and its mechanism of action are largely unknown. The purpose of the present study was to investigate the expression, function and mechanism of PPP1R14D in lung adenocarcinoma (LUAD). In the present study, GEPIA database analysis and immunohistochemistry demonstrated that PPP1R14D was highly expressed in LUAD tissues and that the expression of PPP1R14D in LUAD was negatively correlated with the age of patients and positively correlated with the 8th American Joint Committee on Cancer staging among patients. In addition, Kaplan‑Meier Plotter database analysis showed that PPP1R14D expression was associated with lower survival rates in patients with LUAD. PPP1R14D knockdown significantly inhibited LUAD cell proliferation, migration and invasion and induced LUAD cell arrest at the G1 phase of the cell cycle. Mechanistic analyses revealed that PPP1R14D knockdown may inhibit cell proliferation, migration and invasion by inactivating PKCα/BRAF/MEK/ERK pathway signaling and its downstream key proteins c‑Myc/Cyclin E1‑CDK2 and MMP2/MMP9/Vimentin. Moreover, knockdown of PPP1R14D suppressed tumor growth in vivo. All these results showed that PPP1R14D plays an important role in LUAD tumorigenesis and may serve as a potential prognostic factor and therapeutic target in LUAD.

View Figures

View References

1	Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A and Bray F: Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 71:209–249. 2021. View Article : Google Scholar : PubMed/NCBI
2	Kleczko EK, Kwak JW, Schenk EL and Nemenoff RA: Targeting the complement pathway as a therapeutic strategy in lung cancer. Front Immunol. 10:9542019. View Article : Google Scholar : PubMed/NCBI
3	Lu T, Yang X, Huang Y, Zhao M, Li M, Ma K, Yin J, Zhan C and Wang Q: Trends in the incidence, treatment, and survival of patients with lung cancer in the last four decades. Cancer Manag Res. 11:943–953. 2019. View Article : Google Scholar : PubMed/NCBI
4	Hirsch FR, Scagliotti GV, Mulshine JL, Kwon R, Curran WJ Jr, Wu YL and Paz-Ares L: Lung cancer: Current therapies and new targeted treatments. Lancet. 389:299–311. 2017. View Article : Google Scholar
5	Duffy MJ and Crown J: Biomarkers for predicting response to immunotherapy with immune checkpoint inhibitors in cancer patients. Clin Chem. 65:1228–1238. 2019. View Article : Google Scholar : PubMed/NCBI
6	Zheng Q, Min S and Zhou Q: Identification of potential diagnostic and prognostic biomarkers for LUAD based on TCGA and GEO databases. Biosci Rep. 41:BSR202043702021. View Article : Google Scholar : PubMed/NCBI
7	Denisenko TV, Budkevich IN and Zhivotovsky B: Cell death-based treatment of lung adenocarcinoma. Cell Death Dis. 9:1172018. View Article : Google Scholar : PubMed/NCBI
8	Liu WJ, Du Y, Wen R, Yang M and Xu J: Drug resistance to targeted therapeutic strategies in non-small cell lung cancer. Pharmacol Ther. 206:1074382020. View Article : Google Scholar
9	Zhang J, Sun B, Ruan X, Hou X, Zhi J, Meng X, Zheng X and Gao M: Oncoprotein HBXIP promotes tumorigenesis through MAPK/ERK pathway activation in non-small cell lung cancer. Cancer Biol Med. 18:105–119. 2021. View Article : Google Scholar : PubMed/NCBI
10	Dasgupta P, Kulkarni P, Bhat NS, Majid S, Shiina M, Shahryari V, Yamamura S, Tanaka Y, Gupta RK, Dahiya R and Hashimoto Y: Activation of the Erk/MAPK signaling pathway is a driver for cadmium induced prostate cancer. Toxicol Appl Pharmacol. 401:1151022020. View Article : Google Scholar : PubMed/NCBI
11	Zhang G, Luo X, Wang Z, Xu J, Zhang W, Chen E, Meng Q, Wang D, Huang X, Zhou W and Song Z: TIMP-2 regulates 5-Fu resistance via the ERK/MAPK signaling pathway in colorectal cancer. Aging (Albany NY). 14:297–315. 2022. View Article : Google Scholar
12	Samatar AA and Poulikakos PI: Targeting RAS-ERK signalling in cancer: Promises and challenges. Nat Rev Drug Discov. 13:928–942. 2014. View Article : Google Scholar : PubMed/NCBI
13	Mahapatra L, Andruska N, Mao C, Gruber SB, Johnson TM, Fullen DR, Raskin L and Shapiro DJ: Protein kinase C-α is upregulated by IMP1 in melanoma and is linked to poor survival. Melanoma Res. 29:539–543. 2019. View Article : Google Scholar :
14	Lin R, Bao X, Wang H, Zhu S, Liu Z, Chen Q, Ai K and Shi B: TRPM2 promotes pancreatic cancer by PKC/MAPK pathway. Cell Death Dis. 12:5852021. View Article : Google Scholar : PubMed/NCBI
15	Awad MM, Liu S, Rybkin II, Arbour KC, Dilly J, Zhu VW, Johnson ML, Heist RS, Patil T, Riely GJ, et al: Acquired resistance to KRAS^G12C inhibition in cancer. N Engl J Med. 384:2382–2393. 2021. View Article : Google Scholar : PubMed/NCBI
16	Liu QR, Zhang PW, Lin Z, Li QF, Woods AS, Troncoso J and Uhl GR: GBPI, a novel gastrointestinal- and brain-specific PP1-inhibitory protein, is activated by PKC and inactivated by PKA. Biochem J. 377:171–181. 2004. View Article : Google Scholar
17	Aggen JB, Nairn AC and Chamberlin R: Regulation of protein phosphatase-1. Chem Biol. 7:R13–R23. 2000. View Article : Google Scholar : PubMed/NCBI
18	Zhang W, Shang S, Yang Y, Lu P, Wang T, Cui X and Tang X: Identification of DNA methylation-driven genes by integrative analysis of DNA methylation and transcriptome data in pancreatic adenocarcinoma. Exp Ther Med. 19:2963–2972. 2020.PubMed/NCBI
19	Dang M, Armbruster N, Miller MA, Cermeno E, Hartmann M, Bell GW, Root DE, Lauffenburger DA, Lodish HF and Herrlich A: Regulated ADAM17-dependent EGF family ligand release by substrate-selecting signaling pathways. Proc Natl Acad Sci USA. 110:9776–9781. 2013. View Article : Google Scholar : PubMed/NCBI
20	Eto M: Regulation of cellular protein phosphatase-1 (PP1) by phosphorylation of the CPI-17 family, C-kinase-activated PP1 inhibitors. J Biol Chem. 284:35273–35277. 2009. View Article : Google Scholar : PubMed/NCBI
21	Jin H, Sperka T, Herrlich P and Morrison H: Tumorigenic transformation by CPI-17 through inhibition of a merlin phosphatase. Nature. 442:576–579. 2006. View Article : Google Scholar : PubMed/NCBI
22	Zhao M, Shao Y, Xu J, Zhang B, Li C and Gong J: LINC00466 impacts cell proliferation, metastasis and sensitivity to temozolomide of glioma by sponging miR-137 to regulate PPP1R14B expression. Onco Targets Ther. 14:1147–1159. 2021. View Article : Google Scholar : PubMed/NCBI
23	Jian Y, Kong L, Xu H, Shi Y, Huang X, Zhong W, Huang S, Li Y, Shi D, Xiao Y, et al: Protein phosphatase 1 regulatory inhibitor subunit 14C promotes triple-negative breast cancer progression via sustaining inactive glycogen synthase kinase 3 beta. Clin Transl Med. 12:e7252022. View Article : Google Scholar : PubMed/NCBI
24	Grey J, Jones D, Wilson L, Nakjang S, Clayton J, Temperley R, Clark E, Gaughan L and Robson C: Differential regulation of the androgen receptor by protein phosphatase regulatory subunits. Oncotarget. 9:3922–3935. 2017. View Article : Google Scholar
25	Dang F, Nie L and Wei W: Ubiquitin signaling in cell cycle control and tumorigenesis. Cell Death Differ. 28:427–438. 2021. View Article : Google Scholar :
26	Yang S, Zhang JJ and Huang XY: Orai1 and STIM1 are critical for breast tumor cell migration and metastasis. Cancer Cell. 15:124–134. 2009. View Article : Google Scholar : PubMed/NCBI
27	Salvi N: Intrinsically disordered proteins: Dynamics, binding, and function. Elsevier; 2019
28	Xu C and Zheng J: siRNA against TSG101 reduces proliferation and induces G0/G1 arrest in renal cell carcinoma-involvement of c-myc, cyclin E1, and CDK2. Cell Mol Biol Lett. 24:72019. View Article : Google Scholar
29	Santoni-Rugiu E, Falck J, Mailand N, Bartek J and Lukas J: Involvement of Myc activity in a G(1)/S-promoting mechanism parallel to the pRb/E2F pathway. Mol Cell Biol. 20:3497–3509. 2000. View Article : Google Scholar : PubMed/NCBI
30	Berns K, Hijmans EM and Bernards R: Repression of c-Myc responsive genes in cycling cells causes G1 arrest through reduction of cyclin E/CDK2 kinase activity. Oncogene. 15:1347–1356. 1997. View Article : Google Scholar : PubMed/NCBI
31	Geng X, Chen C, Huang Y and Hou J: The prognostic value and potential mechanism of matrix metalloproteinases among prostate cancer. Int J Med Sci. 17:1550–1560. 2020. View Article : Google Scholar : PubMed/NCBI
32	Andersson P, Yang Y, Hosaka K, Zhang Y, Fischer C, Braun H, Liu S, Yu G, Liu S, Beyaert R, et al: Molecular mechanisms of IL-33-mediated stromal interactions in cancer metastasis. JCI Insight. 3:e1223752018. View Article : Google Scholar
33	Jiang H and Li H: Prognostic values of tumoral MMP2 and MMP9 overexpression in breast cancer: A systematic review and meta-analysis. BMC Cancer. 21:1492021. View Article : Google Scholar : PubMed/NCBI
34	Buttacavoli M, Di Cara G, Roz E, Pucci-Minafra I, Feo S and Cancemi P: Integrated multi-omics investigations of metalloproteinases in colon cancer: Focus on MMP2 and MMP9. Int J Mol Sci. 22:123892021. View Article : Google Scholar : PubMed/NCBI
35	Schaedel L, Lorenz C, Schepers AV, Klumpp S and Köster S: Vimentin intermediate filaments stabilize dynamic microtubules by direct interactions. Nat Commun. 12:37992021. View Article : Google Scholar : PubMed/NCBI
36	Kidd ME, Shumaker DK and Ridge KM: The role of vimentin intermediate filaments in the progression of lung cancer. Am J Respir Cell Mol Biol. 50:1–6. 2014. View Article : Google Scholar :
37	Havel LS, Kline ER, Salgueiro AM and Marcus AI: Vimentin regulates lung cancer cell adhesion through a VAV2-Rac1 pathway to control focal adhesion kinase activity. Oncogene. 34:1979–1990. 2015. View Article : Google Scholar
38	Morrison DK and Davis RJ: Regulation of MAP kinase signaling modules by scaffold proteins in mammals. Annu Rev Cell Dev Biol. 19:91–118. 2003. View Article : Google Scholar : PubMed/NCBI
39	Meyer N and Penn LZ: Reflecting on 25 years with MYC. Nat Rev Cancer. 8:976–990. 2008. View Article : Google Scholar : PubMed/NCBI
40	Albihn A, Johnsen JI and Henriksson MA: MYC in oncogenesis and as a target for cancer therapies. Adv Cancer Res. 107:163–224. 2010. View Article : Google Scholar : PubMed/NCBI
41	Chu J, Li Y, Deng Z, Zhang Z, Xie Q, Zhang H, Zhong W and Pan B: IGHG1 regulates prostate cancer growth via the MEK/ERK/c-Myc pathway. Biomed Res Int. 2019:72015622019. View Article : Google Scholar : PubMed/NCBI
42	Wang Y, Yang S, Zhang S and Wu X: Oxymatrine inhibits proliferation and migration of vulvar squamous cell carcinoma cells via attenuation of the RAS/RAF/MEK/ERK pathway. Cancer Manag Res. 12:2057–2067. 2020. View Article : Google Scholar : PubMed/NCBI
43	Lin F, Chengyao X, Qingchang L, Qianze D, Enhua W and Yan W: CRKL promotes lung cancer cell invasion through ERK-MMP9 pathway. Mol Carcinog. 54(Suppl 1): E35–E44. 2015. View Article : Google Scholar
44	Qin H, Liu X, Li F, Miao L, Li T, Xu B, An X, Muth A, Thompson PR and Zhang X: PAD1 promotes epithelial-mesenchymal transition and metastasis in triple-negative breast cancer cells by regulating MEK1-ERK1/2MMP2 signaling. Cancer lett. 409:30–41. 2017. View Article : Google Scholar : PubMed/NCBI
45	Zhang H, Shen B, Swinarska JT, Li W, Xiao K and He P: 9-Hydroxypheophorbide α-mediated photodynamic therapy induces matrix metalloproteinase-2 (MMP-2) and MMP-9 down-regulation in Hep-2 cells via ROS-mediated suppression of the ERK pathway. Photodiagnosis Photodyn Ther. 11:55–62. 2014. View Article : Google Scholar : PubMed/NCBI
46	Isakov N: Protein kinase C (PKC) isoforms in cancer, tumor promotion and tumor suppression. Semin Cancer Biol. 48:36–52. 2018. View Article : Google Scholar
47	Ricciarelli R and Azzi A: Regulation of recombinant PKC alpha activity by protein phosphatase 1 and protein phosphatase 2A. Arch Biochem Biophys. 355:197–200. 1998. View Article : Google Scholar : PubMed/NCBI
48	Luo W, Xu C, Ayello J, Dela Cruz F, Rosenblum JM, Lessnick SL and Cairo MS: Protein phosphatase 1 regulatory subunit 1A in ewing sarcoma tumorigenesis and metastasis. Oncogene. 37:798–809. 2018. View Article : Google Scholar